Kristina Sjöblom Nygren
Director/Board Member chez INFANT BACTERIAL THERAPEUTICS AB
Fortune : 748 $ au 31/03/2024
Profil
Kristina Sjöblom Nygren is an Independent Director at Infant Bacterial Therapeutics AB since 2018.
She was previously a Group Director-Development at Astrazeneca AG from 2007 to 2008 and a Medical Director at Pfizer AG from 1998 to 2003.
She also served as the Chief Medical Officer, EVP & Head-Development at Santhera Pharmaceuticals Holding AG from 2017 to 2020.
Additionally, she was a Vice President & Head-Clinical Development at Swedish Orphan Biovitrum AB.
Dr. Sjöblom Nygren holds a doctorate degree from Karolinska Institutet.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2022 | 100 ( 0,00% ) | 748 $ | 31/03/2024 |
Postes actifs de Kristina Sjöblom Nygren
| Sociétés | Poste | Début |
|---|---|---|
| INFANT BACTERIAL THERAPEUTICS AB | Director/Board Member | 15/05/2018 |
Anciens postes connus de Kristina Sjöblom Nygren
| Sociétés | Poste | Fin |
|---|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Chief Tech/Sci/R&D Officer | 31/12/2020 |
| Astrazeneca AG | Corporate Officer/Principal | 01/01/2008 |
| Pfizer AG | Chief Tech/Sci/R&D Officer | 01/01/2003 |
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - |
Formation de Kristina Sjöblom Nygren
| Karolinska Institutet | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| INFANT BACTERIAL THERAPEUTICS AB | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Astrazeneca AG | |
| Pfizer AG |
